Efficacy, safety and indication of newly developed insulin analogs
Kobayashi, T.
Nihon Rinsho. Japanese Journal of Clinical Medicine 59(11): 2165-2172
2001
ISSN/ISBN: 0047-1852 PMID: 11712402 Document Number: 539690
A newly developed fast-acting analogs of human insulin can attain more physiological plasma profiles than those of regular human insulin. These pharmacokinetic plasma profiles have greater merits than those of regular human insulin. These pharmacokinetic properties allow for good glycemic control especially after meal with subsequent reduction of HbA1c levels during intensive insulin therapy. Furthermore, the frequencies of hypoglycemia are reduced by using fast-acting human insulin analogs. Long-term uses of these analogs do not have adverse effects including carcinogenesis and do not enhance the growth of vascular smooth muscle tissue. These analogs do not cause insulin allergy. A few reports describe beneficial effect on lipoatrophy of the subcutaneous tissues induced by human regular insulin treatment. Fast-absorbing and fast-acting insulin analog will be suitable for the treatment of type 1 diabetic patients with continuous subcutaneous insulin infusion(CSII).